Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Single-Ascending-Dose Study of EN-374, a Helper-Dependent Adenoviral-Based Gene Therapy, in Participants With X-Linked Chronic Granulomatous Disease

NCT06876363 is registered in ClinicalTrials.gov with Ensoma as lead sponsor.

NCT NCT06876363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06876363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Single-Ascending-Dose Study of EN-374, a Helper-Dependent Adenoviral-Based Gene Therapy, in Participants With X-Linked Chronic Granulomatous Disease
Lead sponsor
Ensoma
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 5, 2025
Completion date
December 31, 2027
Enrollment
15 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked chronic granulomatous disease